WEBULL
WebtradeDownload

Replimune Group (REPL) After Results And A New CCO, Is The Valuation Too Rich

Simply Wall St · 2d ago

Replimune Group (REPL) has drawn attention after reporting first quarter 2026 results, which showed a net loss of US$69.77 million, and appointing experienced oncology commercial leader Michelle DiNapoli as Chief Commercial Officer.

The latest move in Replimune Group’s share price has been sharp, with a 1-month share price return of 62.89% and a 90-day share price return of 236.17% taking the stock to US$15.80. The 1-year total shareholder return of 178.17% contrasts with a 5-year total shareholder return that remains significantly lower.

Capture sharp moves similar to those in Replimune Group by scanning a curated list of 18 high quality undiscovered gems that feature strong fundamentals and potential for a fuller market reaction.

Replimune Group now has a seasoned oncology leader in place and a share price that has already moved significantly. The key issue for investors is whether the current valuation still reflects the risks and rewards on offer.

Preferred Price-to-Book Multiple of 14.1x: Is it justified?

On a headline metric, Replimune Group trades on a P/B ratio of 14.1x, compared with a peer average of 3.5x and a broader US biotechs industry average of 2.5x. That is a strong premium while the last close sits at $15.80 and the company remains loss making.

The P/B ratio compares the stock price to the company’s book value per share. For a clinical stage biotech like Replimune Group with no material revenue and a net loss of $297.01m, investors are effectively paying well above the accounting value of assets for future pipeline potential and forecast growth.

That kind of premium usually implies the market is placing significant weight on projected revenue growth and eventual monetisation of the oncolytic immunotherapy pipeline. At the same time, Replimune Group is currently unprofitable, is forecast to remain unprofitable over the next 3 years, has reported higher losses over the past 5 years, and has relied on higher risk funding sources and recent shareholder dilution.

Against that backdrop, the 14.1x P/B ratio looks rich next to both the US biotechs industry at 2.5x and the peer set at 3.5x. The market is valuing each dollar of book equity in Replimune Group at several times the level seen elsewhere in the sector, which leaves little room for disappointment if the business trajectory does not match these expectations.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 14.1x (OVERVALUED)

However, you still face clear risks with Replimune Group, including ongoing heavy net losses of US$297.01m and a history of shareholder dilution.

Find out about the key risks to this Replimune Group narrative.

Another view on Replimune Group’s value

While the 14.1x P/B ratio makes Replimune Group look expensive versus peers, the SWS DCF model points the other way. It estimates a future cash flow value of $132.21 per share versus the current $15.80. This implies a very large gap that raises questions about which signal investors should pay more attention to.

Look into how the SWS DCF model arrives at its fair value.

REPL Discounted Cash Flow as at Aug 2026
REPL Discounted Cash Flow as at Aug 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Replimune Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on Replimune Group, the key question is how you weigh those risks against the potential rewards. To size up both sides of the story using our structured checklist, take a close look at the 2 key rewards and 5 important warning signs.

Looking for more investment ideas beyond Replimune Group?

If Replimune Group has sharpened your focus on risk and reward, broaden your watchlist now so you do not miss other opportunities shaping the next phase of the market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.